Celgene Raises Long-Term Guidance, But Q4 Falls Short

By | January 13, 2014

Scalper1 News

SAN FRANCISCO — Big-cap biotech Celgene (CELG) announced preliminary 2013 results on Monday and raised its long-term guidance, but that fell short of Wall Street’s bullish expectations, driving shares down on the stock market today. At the annual JPMorgan Healthcare Conference in San Francisco, Celgene executives said 2013 revenue totaled $6.5 billion, a bit above analysts’ consensus and up about $1 billion from 2012. Earnings of $3.96 a share Scalper1 News

Scalper1 News